Assessment of Cancer Concerns at the End of Treatment (ACE)
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/8/2016 |
| Start Date: | July 2014 |
| Contact: | Linda Jacobs, PhD |
| Email: | PennCancerTrials@emergingmed.com |
| Phone: | 855-216-0098 |
This study will describe patient-reported symptom burden and concerns, quality of life
(QOL), and health behaviors of breast cancer(BC) survivors who have completed initial
treatments (e.g., surgery, chemotherapy, and/or radiotherapy), assess the feasibility of
using a web-based platform to collect patient-reported outcome (PRO) data, and evaluate
provider satisfaction following delivery of an electronic health record (HER)/EPIC summary
of these PROs. Secondary aims will estimate differences in referral to available services
between those providers exposed to the PRO summary and historical controls. BC survivors who
have completed initial treatment and present within the first year following treatment for
an end of treatment (EOT)/survivorship focused visit will be the focus of this study.
(QOL), and health behaviors of breast cancer(BC) survivors who have completed initial
treatments (e.g., surgery, chemotherapy, and/or radiotherapy), assess the feasibility of
using a web-based platform to collect patient-reported outcome (PRO) data, and evaluate
provider satisfaction following delivery of an electronic health record (HER)/EPIC summary
of these PROs. Secondary aims will estimate differences in referral to available services
between those providers exposed to the PRO summary and historical controls. BC survivors who
have completed initial treatment and present within the first year following treatment for
an end of treatment (EOT)/survivorship focused visit will be the focus of this study.
Inclusion Criteria:
1. Diagnosed with invasive, non-metastatic BC (Stage I, II, or III) without hematogenous
or distant metastases
2. Have completed initial treatment (chemotherapy, radiotherapy, and/or surgery). May
still be receiving hormonal or targeted therapy (e.g., tamoxifen, aromatase
inhibitors).
3. Within 1 year of completing primary treatment
4. Scheduled for an EOT visit
5. Age 18 years or older
6. Can understand written English
7. Have internet access and a working email address
Exclusion Criteria:
1. Diagnosed with non-invasive (Stage 0/DCIS) or metastatic (Stage IV) cancer or
hematogenous or distant metastatic disease
2. No working email address -
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-6065
Phone: 855-216-0098
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
Click here to add this to my saved trials
